252 related articles for article (PubMed ID: 15980690)
1. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Gerber JG; Rosenkranz SL; Fichtenbaum CJ; Vega JM; Yang A; Alston BL; Brobst SW; Segal Y; Aberg JA;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):307-12. PubMed ID: 15980690
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
4. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
[TBL] [Abstract][Full Text] [Related]
5. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR
Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.
Fichtenbaum CJ; Gerber JG; Rosenkranz SL; Segal Y; Aberg JA; Blaschke T; Alston B; Fang F; Kosel B; Aweeka F;
AIDS; 2002 Mar; 16(4):569-77. PubMed ID: 11873000
[TBL] [Abstract][Full Text] [Related]
8. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
Jones P; Kafonek S; Laurora I; Hunninghake D
Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
[TBL] [Abstract][Full Text] [Related]
9. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Kokudai M; Inui N; Takeuchi K; Sakaeda T; Kagawa Y; Watanabe H
J Clin Pharmacol; 2009 May; 49(5):568-73. PubMed ID: 19398603
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
[TBL] [Abstract][Full Text] [Related]
11. A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin.
Moon A; Smith T
Clin Ther; 2002 Apr; 24(4):653-61. PubMed ID: 12017409
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Hilleman DE; Wurdeman RL; Lenz TL
Pharmacotherapy; 2001 Apr; 21(4):410-5. PubMed ID: 11310513
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Kovarik JM; Hartmann S; Hubert M; Berthier S; Schneider W; Rosenkranz B; Rordorf C
J Clin Pharmacol; 2002 Feb; 42(2):222-8. PubMed ID: 11831546
[TBL] [Abstract][Full Text] [Related]
15. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers.
Teng R; Mitchell PD; Butler KA
Eur J Clin Pharmacol; 2013 Mar; 69(3):477-87. PubMed ID: 22922682
[TBL] [Abstract][Full Text] [Related]
17. Investigation of combined CYP3A4 inductive/inhibitory properties by studying statin interactions: a model study with the renin inhibitor ACT-178882.
Dingemanse J; Nicolas LB; van Bortel L
Eur J Clin Pharmacol; 2014 Jun; 70(6):675-84. PubMed ID: 24728182
[TBL] [Abstract][Full Text] [Related]
18. Comparison of statins in hypertriglyceridemia.
Stein EA; Lane M; Laskarzewski P
Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
[TBL] [Abstract][Full Text] [Related]
19. Interaction between ritonavir and statins.
Piliero PJ
Am J Med; 2002 Apr; 112(6):510-1. PubMed ID: 11959074
[No Abstract] [Full Text] [Related]
20. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
